ASTM
سعر الشراء بالسعر الحالي 1.05
البيع بسعر 1.5
سبب التوصية :
http://finance.yahoo.com/mp#astm
الستوب لووز 0.7
Aastrom Biosciences, Inc. (NasdaqSC: ASTM) today announced that it has
completed all requirements to affix the CE Mark on its DCV-II kit in the
European Union. This is the third of the Company's dendritic cell production
kits to use the CE Mark. The DCV-II kit operates on the AastromReplicell(TM)
System instrument platform, and produces peptide-loaded dendritic cells that
are being investigated in clinical trials as therapeutic cancer vaccines. The
CE Mark allows Aastrom to market and sell DCV-II kits in Europe; the kits are
available as well in the United States for clinical research use.
Dendritic cells loaded with specific tumor-associated fragments called
peptides are one of the new approaches currently being clinically investigated
to induce a therapeutic immune response to different forms of cancer. These
tumor-associated peptides include melanoma, colon, breast and prostate cancer-
associated peptides. The AastromReplicell(TM) System and the DCV-II vaccine
production kits facilitate such studies by allowing researchers and
investigators to produce sufficient clinical quantities of dendritic cells in
an automated, closed-system, Good Manufacturing Practices (GMP)-compliant
process. In addition, like the previously released DC-I and DCV-I kits, the
DCV-II kit offers clinical investigators the ability to produce dendritic
cells loaded with a broad array of tumor antigens, and are intended to bring
forward a variety of vaccines based on Aastrom's technology.
المفضلات